

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934**

February 3, 2017 (January 30, 2017)
Date of Report (Date of earliest event reported)



HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

WYOMING
(State or other jurisdiction of
incorporation or organization)

000-55364
(Commission
File Number)

36-4787690
(I.R.S. Employer
Identification No.)

(Exact name of registrant as specified in charter)

Suite 400, 41 University Drive
Newtown, Pennsylvania, 18940
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (215) 809-2018

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 30, 2017, Heliuss Medical Technologies, Inc. (the "Company") received a written letter of resignation from Savio Chiu stating that he has resigned from his position on the Company's Board of Directors (the "Board"), effective immediately. Mr. Chiu resigned from the Board to pursue other business opportunities. Mr. Chiu's resignation did not result from any disagreement with the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Resignation letter dated January 30, 2017 from Savio Chiu

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HELIUS MEDICAL TECHNOLOGIES, INC.

Dated: February 3, 2017

By: /s/ Joyce LaViscount
Joyce LaViscount, Chief Financial Officer

RESIGNATION OF DIRECTOR

TO: Helius Medical Technologies, Inc.
(the “**Company**”)

I hereby resign as a director of the Company. I confirm that there is no compensation or other indebtedness owing to me, and that I have no claims against the Company.

DATED: January 30, 2017

/s/Savio Chiu
Savio Chiu